Entries in TEVA (1)


Adding TEVA Pharmaceuticals to My Portfolios at Kapitall

I used the market pullback over the last couple days to add the pharmaceutical company TEVA (TEVA $49.22) to my portfolios. They have a good generic drug business which ads stability. With a POP (forward price earnings ratio) of 9 and a dividend yield of 1.6%, the company is also attractively valued.

I think the entire pharmaceutical sector offers a compelling value opportunity.

Click to read more ...